Danielle I. Stanisic

Danielle I. Stanisic

Auto-generated profile, based on publicly available information

Danielle I. Stanisic

Institute for Biomedicine and Glycomics Griffith University Southport QLD Australia

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Infection and Immunity
Verified
Journal Article
Closed access
DSDanielle I. Stanisic
Danielle I. Stanisic
JRJack Richards
Jack Richards
FMFiona J. McCallum
Fiona J. McCallum
PMPascal Michon
Pascal Michon
CKChristopher L. King
Christopher L. King
JBJames G. Beeson
James G. Beeson
Substantial evidence indicates that antibodies to Plasmodium falciparum merozoite antigens play a role in protection from malaria, although the precise targets and mechanisms mediating immunity remain unclear. Different malaria antigens induce distinct immunoglobulin G (IgG) subclass responses, but the importance of different responses in protective immunity from malaria is not known and the factors determining subclass responses in vivo are poorly understood. We examined IgG and IgG subclass responses to the merozoite antigens MSP1-19 (the 19-kDa C-terminal region of merozoite surface protein 1), MSP2 (merozoite surface protein 2), and AMA-1 (apical membrane antigen 1), including different polymorphic variants of these antigens, in a longitudinal cohort of children in Papua New Guinea. IgG1 and IgG3 were the predominant subclasses of antibodies to each antigen, and all antibody responses increased in association with age and exposure without evidence of increasing polarization toward one subclass. The profiles of IgG subclasses differed somewhat for different alleles of MSP2 but not for different variants of AMA-1. Individuals did not appear to have a propensity to make a specific subclass response irrespective of the antigen. Instead, data suggest that subclass responses to each antigen are generated independently among individuals and that antigen properties, rather than host factors, are the major determinants of IgG subclass responses. High levels of AMA-1-specific IgG3 and MSP1-19-specific IgG1 were strongly predictive of a reduced risk of symptomatic malaria and high-density P. falciparum infections. However, no antibody response was significantly associated with protection from parasitization per se. Our findings have major implications for understanding human immunity and for malaria vaccine development and evaluation.

4 February 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ELEnmoore Lin
Enmoore Lin
BKBenson Kiniboro
Benson Kiniboro
LGLaurie Gray
Laurie Gray
SDStuart Dobbie
Stuart Dobbie
LRLeanne Robinson
Leanne Robinson
IMIvo Mueller
Ivo Mueller
Where P. vivax and P. falciparum occur in the same population, the peak burden of P. vivax infection and illness is often concentrated in younger age groups. Experiences from malaria therapy patients indicate that immunity is acquired faster to P. vivax than to P. falciparum challenge. There is however little prospective data on the comparative risk of infection and disease from both species in young children living in co-endemic areas. A cohort of 264 Papua New Guinean children aged 1-3 years (at enrolment) were actively followed-up for Plasmodium infection and febrile illness for 16 months. Infection status was determined by light microscopy and PCR every 8 weeks and at each febrile episode. A generalised estimating equation (GEE) approach was used to analyse both prevalence of infection and incidence of clinical episodes. A more pronounced rise in prevalence of P. falciparum compared to P. vivax infection was evident with increasing age. Although the overall incidence of clinical episodes was comparable (P. falciparum: 2.56, P. vivax 2.46 episodes / child / yr), P. falciparum and P. vivax infectious episodes showed strong but opposing age trends: P. falciparum incidence increased until the age of 30 months with little change thereafter, but incidence of P. vivax decreased significantly with age throughout the entire age range. For P. falciparum, both prevalence and incidence of P. falciparum showed marked seasonality, whereas only P. vivax incidence but not prevalence decreased in the dry season. Under high, perennial exposure, children in PNG begin acquiring significant clinical immunity, characterized by an increasing ability to control parasite densities below the pyrogenic threshold to P. vivax, but not to P. falciparum, in the 2nd and 3rd year of life. The ability to relapse from long-lasting liver-stages restricts the seasonal variation in prevalence of P. vivax infections.

10 September 2012 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
IBInoni Betuela
Inoni Betuela
ARAnna Rosanas-Urgell
Anna Rosanas-Urgell
BKBenson Kiniboro
Benson Kiniboro
DSDanielle I. Stanisic
Danielle I. Stanisic
LSLornah Samol
Lornah Samol
IMIvo Mueller
Ivo Mueller
Background. Plasmodium vivax forms long-lasting hypnozoites in the liver. How much they contribute to the burden of P. vivax malaria in children living in highly endemic areas is unknown.

8 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TLTali Lang
Tali Lang
JLJacinta P. W. Lee
Jacinta P. W. Lee
KEKirstin Elgass
Kirstin Elgass
APAnita A. Pinar
Anita A. Pinar
MTMichelle Tate
Michelle Tate
James HarrisJames Harris
James Harris
Macrophage migration inhibitory factor (MIF) exerts multiple effects on immune cells, as well as having functions outside the immune system. MIF can promote inflammation through the induction of other cytokines, including TNF, IL-6, and IL-1 family cytokines. Here, we show that inhibition of MIF regulates the release of IL-1α, IL-1β, and IL-18, not by affecting transcription or translation of these cytokines, but via activation of the NLRP3 inflammasome. MIF is required for the interaction between NLRP3 and the intermediate filament protein vimentin, which is critical for NLRP3 activation. Further, we demonstrate that MIF interacts with NLRP3, indicating a role for MIF in inflammasome activation independent of its role as a cytokine. These data advance our understanding of how MIF regulates inflammation and identify it as a factor critical for NLRP3 inflammasome activation.

15 October 2010 in Clinical Infectious Diseases
Verified
Journal Article
Open access
JRJack Richards
Jack Richards
DSDanielle I. Stanisic
Danielle I. Stanisic
FFFreya J. I. Fowkes
Freya J. I. Fowkes
LTLivingstone Tavul
Livingstone Tavul
EDElijah Dabod
Elijah Dabod
JBJames G. Beeson
James G. Beeson
Background. Antibodies targeting blood stage antigens are important in protection against malaria, but the principle targets remain unclear. Erythroc

17 June 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CKChristopher L. King
Christopher L. King
PMPascal Michon
Pascal Michon
ASAhmad Rushdi Shakri
Ahmad Rushdi Shakri
AMAlexandra Marcotty
Alexandra Marcotty
DSDanielle Stanisic
Danielle Stanisic
CCChetan E. Chitnis
Chetan E. Chitnis
Individuals residing in malaria-endemic regions acquire protective immunity after repeated infection with malaria parasites; however, mechanisms of protective immunity and their immune correlates are poorly understood. Blood-stage infection with Plasmodium vivax depends completely on interaction of P. vivax Duffy-binding protein (PvDBP) with the Duffy antigen on host erythrocytes. Here, we performed a prospective cohort treatment/reinfection study of children (5–14 years) residing in a P. vivax -endemic region of Papua New Guinea (PNG) in which children were cleared of blood-stage infection and then examined biweekly for reinfection for 25 weeks. To test the hypothesis that naturally acquired binding inhibitory antibodies (BIAbs) targeting PvDBP region II (PvDBPII) provide protection against P. vivax infection, we used a quantitative receptor-binding assay to distinguish between antibodies that merely recognize PvDBP and those that inhibit binding to Duffy. The presence of high-level BIAbs (>90% inhibition of PvDBPII-Duffy binding, n = 18) before treatment was associated with delayed time to P. vivax reinfection diagnosed by light microscopy ( P = 0.02), 55% reduced risk of P. vivax reinfection (Hazard's ratio = 0.45, P = 0.04), and 48% reduction in geometric mean P. vivax parasitemia ( P < 0.001) when compared with children with low-level BIAbs ( n = 148). Further, we found that stable, high-level BIAbs displayed strain-transcending inhibition by reducing reinfection with similar efficiency of PNG P. vivax strains characterized by six diverse PvDBPII haplotypes. These observations demonstrate a functional correlate of protective immunity in vivo and provide support for developing a vaccine against P. vivax malaria based on PvDBPII.